Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: PER, VEN

4iQ Raises $30 Million in Series C Funding, Names Kailash Ambwani as CEO


LOS ALTOS, Calif., Oct. 20, 2020 /PRNewswire/ -- 4iQ, a leader in Cyber Intelligence, today announced $30 million in Series C funding, led by ForgePoint Capital and Benhamou Global Ventures, with participation by C5 Capital, Adara Ventures and the addition of TheVentureCity, which brings a new venture and acceleration model that helps diverse founders achieve global impact. In addition to this new investment, 4iQ is announcing it has appointed Kailash Ambwani as Chief Executive Officer. With Ambwani at the helm, 4iQ will ramp investments in go-to-market activities and accelerate innovation to help customers better anticipate and respond to emerging digital risks.

"As our lives become increasingly digital, the need for cyber intelligence becomes even more critical," said Alberto Yepez, 4iQ Board chair and co-founder and managing director of ForgePoint Capital. "4iQ enables enterprises to understand their digital risk and exposure ? and to take a more proactive approach to identifying threat actors. Under Kailash's strategic guidance, 4iQ is well-positioned to become a leader in the Digital Risk Protection market."

Ambwani brings a proven track record of scaling businesses with more than 20 years of leadership experience, most recently as CEO of Waterline Data, a global leader in data cataloging solutions and applications. Prior to that, Ambwani was President and CEO of Actiance, a leading provider of compliance, security, archiving and eDiscovery for all critical business communications.

"4iQ is at the forefront of understanding modern digital risk and I'm elated to lead the company toward its vision to help every company operationalize that understanding, stop fraud and crime, and make people safer," said Ambwani. "It's no longer enough to keep your own house in order. Exposed credentials continue to proliferate in underground communities, especially in the wake of COVID-19, and so, now more than ever, we must empower investigators to uncover the real identities behind criminal activities and thwart future attacks."

Founded in 2016, with offices in North America and Europe, 4iQ is an adversary intelligence company on a mission to empower intel analysts, security researchers, and criminal investigators with capabilities to discover, uncover, and disrupt adversaries. 4iQ's IDLaketm archives more than 45 billion identity records collected from open sources on the deep and dark web and powers two solutions:

Learn more about 4iQ by visiting www.4iQ.com.

About 4iQ
4iQ provides adversary intelligence that helps organizations measure, monitor and manage digital risk. The 4iQ IDLaketm archives more than 45 billion identity records collected from data breaches and leaks found in open sources, on the surface, social and deep and dark web. It powers 4iQ IDHunttm, a pioneering identity intelligence and attribution analysis solution used by Fraud Investigation Units, Anti-Money Laundering and Financial Crime Intel Units, and advanced Security Operations Centers. The 4iQ IDLaketm also powers 4iQ IDThefttm, used by some of the largest Identity Theft Protection service providers, security vendors and Enterprises to alert millions of consumers of exposed personal information, prevent account takeover and identity theft.

SOURCE 4iQ


These press releases may also interest you

at 11:40
The "Global Needle Coke Market: Focus on Application, Type, Grade, End Use, and Country-Level Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global needle coke market was valued at $3.05...

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 09:35
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research...

at 09:25
The "The U.S. Telehealth Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering The report includes in-depth analyses of: the scope of telehealth usage in the U.S., telehealth user demographics, pros and...

at 09:00
Amid growing concerns about a medical crisis as a result of acute conflict between the government...



News published on and distributed by: